Role of ETA receptors in the regulation of vascular reactivity in rats with congestive heart failure
- 1 August 2000
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 279 (2) , H844-H851
Abstract
Endothelium-derived nitric oxide (NO) and endothelin (ET)-1 interact to regulate vascular tone. In congestive heart failure (CHF), the release and/or the activity of both factors is affected. We hypothesized that the increased ET-1 production associated with CHF may result in a reduced smooth muscle sensitivity to NO. The aim of this study was to evaluate the effects of a chronic treatment with the ETA-receptor (ET receptor A) antagonist LU-135252 (LU) on cerebrovascular reactivity to sodium nitroprusside (SNP) in the rat infarct model of CHF. Rats were subjected to coronary artery ligation and were treated for 4 wk with placebo ( n = 24) or LU (50 mg · kg−1 · day−1, n = 29). CHF was associated with a decreased ( P < 0.05) efficacy of SNP to induce relaxation of isolated middle cerebral arteries. Furthermore, neither NO synthase inhibition with N ω-nitro-l-arginine (l-NNA) nor endothelial denudation affected the efficacy of SNP. Thus the endothelium no longer influences smooth muscle sensitivity to SNP. LU treatment, however, normalized ( P < 0.05) smooth muscle sensitivity to SNP. Sensitivity of ET-1-induced contraction was increased in CHF only in the presence of l-NNA, whereas contraction induced by ETB receptor (receptor B) stimulation was increased ( P < 0.05) in endothelium-denuded vessels. LU treatment restored these changes in reactivity and revealed a significant endothelium-dependent ETB-mediated relaxation after NO synthase inhibition. In conclusion, CHF decreases and uncouples cerebrovascular smooth muscle sensitivity to SNP from endothelial regulation. The observation that chronic ETAblockade restored most of the changes associated with CHF suggests that activation of the ET-1 system importantly contributes to the alteration in vascular reactivity observed in experimental CHF.Keywords
This publication has 34 references indexed in Scilit:
- Mechanism of Nitric Oxide–Induced VasodilatationCirculation Research, 1999
- Elevation of intracellular calcium in smooth muscle causes endothelial cell generation of NO in arteriolesProceedings of the National Academy of Sciences, 1997
- Endothelial dysfunction: Clinical implicationsProgress in Cardiovascular Diseases, 1997
- Nitric Oxide Attenuates the Release of Endothelium-Derived Hyperpolarizing FactorCirculation, 1996
- Endothelin Peptide and Receptors in Human Atherosclerotic Coronary Artery and AortaCirculation Research, 1996
- Nitrates in the treatment of congestive heart failureThe American Journal of Cardiology, 1996
- Enhanced Coronary Vasoconstriction to Endothelin-BReceptor Activation in Experimental Congestive Heart FailureCirculation, 1996
- Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase.Proceedings of the National Academy of Sciences, 1994
- Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscleNature, 1994
- Nitric oxide decreases [Ca2+]i in vascular smooth muscle by inhibition of the calcium currentCell Calcium, 1994